AGIO - アギオス・ファ―マシュ―ティカルズ (Agios Pharmaceuticals Inc.) アギオス・ファ―マシュ―ティカルズ

 AGIOのチャート


 AGIOの企業情報

symbol AGIO
会社名 Agios Pharmaceuticals Inc (アギオス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アジオス・ファーマスーティカルズ(Agios Pharmaceuticals Inc.)はバイオ医薬品会社。同社は根本的に癌と先天性代謝異常(IEM)の治療法を変えるために代謝に対する深い理解と代謝酵素を阻害・活性化できる薬剤を開発する能力を結合して応用しようとする。同社はすでに癌と先天性代謝異常に対して新薬開発の目標を明確・有効にした。同社の2つの進んだ癌プログラムは「IDH1」と「IDH2」と呼ばれるイソクエン酸脱水素酵素1と2の変異を標的とする。同社の薬剤候補は他の細胞に見られるIDH1とIDH2の正常形態に対し、癌に見られるIDH1とIDH2の変異形態を特定する。   アギオス・ファ―マシュ―ティカルズは、がん代謝と先天性代謝異常の分野に特化した米国のバイオ医薬品企業。主製品候補は、変異型イソクエン酸脱水素酵素2「AG-221」及びイソクエン酸デヒドロゲナ―ゼ1「AG-120」。急性骨髄性白血病などの突然変異IDH2を保有する癌または、突然変異IDH1を保有する癌患者用の強力な阻害剤。   Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
本社所在地 88 Sidney Street Cambridge MA 02139 USA
代表者氏名 David P. Schenkein David P. Schenkein
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 617-649-8600
設立年月日 39295
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 382人
url www.agios.com
nasdaq_url https://www.nasdaq.com/symbol/agio
adr_tso
EBITDA EBITDA(百万ドル) -329.37600
終値(lastsale) 68.07
時価総額(marketcap) 3947554648.32
時価総額 時価総額(百万ドル) 3819.391
売上高 売上高(百万ドル) 70.33300
企業価値(EV) 企業価値(EV)(百万ドル) 3102.486
当期純利益 当期純利益(百万ドル) -324.99200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Agios Pharmaceuticals Inc revenues increased from $21.9M to $49.2M. Net loss increased 7% to $159.6M. Revenues reflect Collaboration revenue - related party increase of 54% to $33.7M. Higher net loss reflects Research and development increase of 15% to $146.6M (expense) General and administrative increase of 66% to $38.5M (expense).

 AGIOのテクニカル分析


 AGIOのニュース

   The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts  2020/07/02 12:21:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) AbbVie Inc (NYSE: ABBV ) ADC Therapeutics SA (NYSE: ADCT ) Affimed NV (NASDAQ: AFMD ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akero Therapeutics Inc (NASDAQ: AKRO ) ( announced positive results for mid-stage study of NASH drug) Amgen, Inc. (NASDAQ: AMGN ) (reacted to a favorable court ruling on its Enbrel patent litigation) Aptinyx Inc (NASDAQ: APTX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Crispr Therapeutics AG (NASDAQ: CRSP ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) Legend Biotech Corp (NASDAQ: LEGN ) Liminal BioSciences Inc (NASDAQ: LMNL ) (announced commencement of convalescent plasma collection from donors who have recovered from COVID-19 and upcoming catalysts) Natera Inc (NASDAQ: NTRA ) Opko Health Inc. (NASDAQ: OPK ) Pacira Biosciences Inc (NASDAQ: PCRX ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) Twist Bioscience Corp (NASDAQ: TWST ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) (announced FDA approval for drug to treat long-chain fatty acid oxidation disorders) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 1) ADiTx Therapeutics Inc (NASDAQ: ADTX ) Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) Generation Bio Co (NASDAQ: GBIO ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Repare Therapeutics Inc (NASDAQ: RPTX ) Stocks In Focus Novartis Finalizes $678M Settlement In US Lawsuit Over Kickbacks Paid To Doctors Novartis AG (NYSE: NVS ) said it has finalized its previously disclosed agreement with the U.S.
   Has Agios Pharmaceuticals (AGIO) Outpaced Other Medical Stocks This Year?  2020/06/10 15:30:16 Zacks Investment Research
Is (AGIO) Outperforming Other Medical Stocks This Year?
   Thermo Fisher Scientific to Co-develop a Global Companion Diagnostic for Low-grade Glioma with Agios Pharmaceuticals  2020/06/09 11:00:00 PR Newswire
CARLSBAD, Calif., June 9, 2020 /PRNewswire/ -- Thermo Fisher Scientific today announced that it has expanded its strategic partnership with Agios Pharmaceuticals by adding the co-development of a second companion diagnostic (CDx) for oncology to their existing agreement. The CDx will…
   Why Is Agios Pharmaceuticals (AGIO) Up 25.8% Since Last Earnings Report?  2020/05/30 15:31:41 Zacks Investment Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Moving Average Crossover Alert: Agios Pharmaceuticals  2020/05/28 15:56:00 Zacks Investment Research
Agios Pharmaceuticals, Inc. (AGIO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
   Has Agios Pharmaceuticals (AGIO) Outpaced Other Medical Stocks This Year?  2020/06/10 15:30:16 Zacks Investment Research
Is (AGIO) Outperforming Other Medical Stocks This Year?
   Thermo Fisher Scientific to Co-develop a Global Companion Diagnostic for Low-grade Glioma with Agios Pharmaceuticals  2020/06/09 11:00:00 PR Newswire
CARLSBAD, Calif., June 9, 2020 /PRNewswire/ -- Thermo Fisher Scientific today announced that it has expanded its strategic partnership with Agios Pharmaceuticals by adding the co-development of a second companion diagnostic (CDx) for oncology to their existing agreement. The CDx will…
   Why Is Agios Pharmaceuticals (AGIO) Up 25.8% Since Last Earnings Report?  2020/05/30 15:31:41 Zacks Investment Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Moving Average Crossover Alert: Agios Pharmaceuticals  2020/05/28 15:56:00 Zacks Investment Research
Agios Pharmaceuticals, Inc. (AGIO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
   Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?  2020/05/21 15:30:14 Zacks Investment Research
Is (AGIO) Outperforming Other Medical Stocks This Year?
   Why Is Agios Pharmaceuticals (AGIO) Up 25.8% Since Last Earnings Report?  2020/05/30 15:31:41 Zacks Investment Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Moving Average Crossover Alert: Agios Pharmaceuticals  2020/05/28 15:56:00 Zacks Investment Research
Agios Pharmaceuticals, Inc. (AGIO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
   Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?  2020/05/21 15:30:14 Zacks Investment Research
Is (AGIO) Outperforming Other Medical Stocks This Year?
   Will Agios Pharmaceuticals Continue to Surge Higher?  2020/05/13 14:49:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor Agios Pharmaceuticals
   Why Agios (AGIO) Stock Might be a Great Pick  2020/05/07 14:18:00 Zacks Investment Research
Agios (AGIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アギオス・ファ―マシュ―ティカルズ AGIO Agios Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)